TickerFacts.

Zura Bio Ltd (ZURA): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$64.93M
Year ended 2025-12-31
2024-12-31: -$28.15M2025-12-31: -$64.93M-$64.93M
2024-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$64.93Mn/m2026-03-19, From 2025-01-01
2024-12-31-$28.15Mn/a2026-03-19, From 2024-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Zura Bio Ltd (ZURA)2025-12-31-$64.93Mn/m
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$19.44Mn/m
Humacyte, Inc. (HUMA)2025-12-31-$105.93Mn/m
Kalaris Therapeutics, Inc. (KLRS)2025-12-31-$38.57Mn/a
Acumen Pharmaceuticals, Inc. (ABOS)2025-12-31-$115.63Mn/m
Candel Therapeutics, Inc. (CADL)2025-12-31-$38.90Mn/m
Pelthos Therapeutics Inc. (PTHS)2025-12-31-$22.69Mn/m
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31-$79.34Mn/m
Surrozen, Inc. (SRZN)2025-12-31-$30.37Mn/m

Compare ZURA, LCTX, HUMA, KLRS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗